Caption Management’s Definium Therapeutics DFTX Stock Holding History

Caption Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Buy	45,000 +11,242	+33%	+$278K	0.01%	890
2026 Q1	$638K	Buy	+33,758	New	+$573K	﹤0.01%	1147

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Caption Management's DFTX Position: Q2 2026 in Review

Caption Management increased its Definium Therapeutics (DFTX) stake by 33% in Q2 2026, buying an estimated $278K and bringing the position to 45,000 shares worth $2.12M. The position accounts for 0.01% of the portfolio, ranked #890.

Caption Management first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Caption Management held 45,000 shares of Definium Therapeutics worth $2.12M as of Q2 2026.
Caption Management bought 11,242 Definium Therapeutics shares in Q2 2026, an estimated $278K.
Definium Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #890 holding.
Caption Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.